Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30166560 | 1.00 | DGAT1 (0.33) | DGAT1NPC1MAPT | |
| SCHEMBL24753784 | 0.75 | DGAT1 (0.32) | DGAT1NPC1 | |
| SCHEMBL25461534 | 0.74 | NPC1 (0.34) | DGAT1NPC1 | |
| SCHEMBL31458608 | 0.73 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL30606259 | 0.72 | ADORA2A (0.37) | MAPT | |
| SCHEMBL25406827 | 0.72 | ADORA2A (0.37) | MAPT | |
| SCHEMBL18153384 | 0.71 | DGAT1 (0.38) | DGAT1NPC1 | |
| SCHEMBL25239263 | 0.71 | DGAT1 (0.33) | DGAT1NPC1MAPT | |
| SCHEMBL31741718 | 0.70 | DGAT1 (0.35) | DGAT1NPC1 | |
| SCHEMBL16608476 | 0.69 | DGAT1 (0.38) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368616-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-12-04 | — | — | US | disclosed |
| US-20250206718-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4495110-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-01-22 | — | — | EP | disclosed |
| EP-4393916-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4393916-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-117813299-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023174406-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023025320-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206718-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, EGFR, WEE2 | DGAT1 3132/4885NPC1 1201/4885MAPT 3836/4885 |
| US-20250368616-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, EGFR | DGAT1 3519/4885NPC1 1779/4885MAPT 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.